SCHEMBL4290407

SCHEMBL4290407

Cc1cc(C(=O)Nc2nccs2)ccc1NC(=O)CC1CCCC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.68
ADORA1 P30542 4/20 0.68
EPHX2 P34913 1/20 0.64
MAPK14 Q16539 1/20 0.54
MEN1 O00255 5/20 0.52
KMT2A Q03164 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
USP2 O75604 2/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
HSD17B10 Q99714 2/20 0.52
TSHR P16473 1/20 0.52
STAT3 P40763 1/20 0.52
HTT P42858 1/20 0.52
RAB9A P51151 6/20 0.51
NPC1 O15118 5/20 0.51
MAPK1 P28482 2/20 0.49
POLB P06746 2/20 0.49
ALDH1A1 P00352 1/20 0.48
ESR2 Q92731 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4292645 0.88 ADORA2A (0.71) ADORA2AADORA1EPHX2MAPK14MEN1
SCHEMBL3193542 0.88 ADORA2A (0.67) ADORA2AADORA1EPHX2MAPK14MEN1
SCHEMBL4286187 0.88 ADORA2A (0.67) ADORA2AADORA1EPHX2MAPK14MEN1
SCHEMBL4285963 0.88 EPHX2 (0.64) ADORA2AADORA1EPHX2MAPK14MEN1
SCHEMBL4293164 0.87 ADORA2A (0.69) ADORA2AADORA1EPHX2MAPK14MEN1
SCHEMBL4290829 0.85 ADORA2A (0.61) ADORA2AADORA1EPHX2MAPK14MEN1
SCHEMBL4288819 0.84 EPHX2 (0.59) ADORA2AADORA1EPHX2MAPK14MEN1
SCHEMBL4287595 0.84 ADORA2A (0.62) ADORA2AADORA1MAPK14MEN1KMT2A
SCHEMBL4286580 0.83 EPHX2 (0.73) ADORA2AEPHX2MEN1KMT2ASMN1; SMN2
Cycloheptane SCHEMBL5501371 0.82 ADORA2A (0.69) ADORA2AADORA1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US claimed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP claimed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP claimed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN claimed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP claimed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US claimed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO claimed
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885EPHX2 898/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885EPHX2 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.